Immix Biopharma, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IMMX, updated each market day.
IMMX AI Sentiment
AI sees no strong directional signal for Immix Biopharma, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Immix Biopharma, Inc. Common Stock
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Sector
Exchange
Market Cap
$516,867,897
Cap Tier
Employees
21
Headquarters
LOS ANGELES, CA
Listed Since
Dec. 16, 2021
Website
IMMX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IMMX Volatility
Immix Biopharma, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
